Literature DB >> 23906016

Artesunate possesses anti-leukemia properties that can be enhanced by arsenic trioxide.

Ying Li1, Lili Feng, Ying Li1, Wen Jiang, Ningning Shan, Xin Wang.   

Abstract

Artesunate (ART), an effective and safe anti-malaria drug, also exhibits anticancer activity. We studied the effects of ART on proliferation and apoptosis of human K562 and U937 leukemia cell lines. MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] assay demonstrated that ART inhibits cell growth in a dose- and time-dependent manner. Based on the findings obtained from light, fluorescence and transmission electron microscopy and propidium iodide staining, the effect of ART was shown to be mediated through apoptosis. In parallel, ART treatment increased Fas expression, while it decreased the c-Fos level in K562 cells. Furthermore, co-treatment with arsenic trioxide (ATO) significantly facilitated ART-induced K562 cell apoptosis. These findings demonstrated that ART had an antitumor activity against K562 and U937 leukemia cells, largely due to inhibition of proliferation and induction of apoptosis via the intrinsic pathway; and this tumoricidal function could be enhanced by ATO.

Entities:  

Keywords:  Artesunate; anti-leukemia; arsenic trioxide

Mesh:

Substances:

Year:  2013        PMID: 23906016     DOI: 10.3109/10428194.2013.829573

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  9 in total

Review 1.  Artemisinin-type drugs for the treatment of hematological malignancies.

Authors:  R I Mancuso; M A Foglio; S T Olalla Saad
Journal:  Cancer Chemother Pharmacol       Date:  2020-11-03       Impact factor: 3.333

Review 2.  Malaria and Cancer: a critical review on the established associations and new perspectives.

Authors:  Toby Ellis; Elvis Eze; Bahijja Tolulope Raimi-Abraham
Journal:  Infect Agent Cancer       Date:  2021-05-13       Impact factor: 2.965

3.  Arsenic trioxide inhibits tumor-induced myeloid-derived suppressor cells and enhances T-cell activity.

Authors:  Qingmin Gao; Jingwei Jiang; Zhaohui Chu; Hao Lin; Xinli Zhou; Xiaohua Liang
Journal:  Oncol Lett       Date:  2017-02-06       Impact factor: 2.967

4.  Farnesylthiosalicylic acid sensitizes hepatocarcinoma cells to artemisinin derivatives.

Authors:  Liping Wu; Yilin Pang; Guiqi Qin; Gaina Xi; Shengnan Wu; Xiaoping Wang; Tongsheng Chen
Journal:  PLoS One       Date:  2017-02-09       Impact factor: 3.240

Review 5.  Therapeutic Potential of Certain Terpenoids as Anticancer Agents: A Scoping Review.

Authors:  Sareh Kamran; Ajantha Sinniah; Mahfoudh A M Abdulghani; Mohammed Abdullah Alshawsh
Journal:  Cancers (Basel)       Date:  2022-02-22       Impact factor: 6.639

6.  Artesunate enhances adriamycin cytotoxicity by inhibiting glycolysis in adriamycin-resistant chronic myeloid leukemia K562/ADR cells.

Authors:  Li Chen; Chao Wang; Ning Hu; Hongmian Zhao
Journal:  RSC Adv       Date:  2019-01-09       Impact factor: 4.036

7.  Construction of a BALB/c-Nu Mouse Model of Invasive Bladder Carcinoma and Preliminary Studies on the Treatment of Bladder Tumors through Internal Iliac Arterial Infusion of Albumin-Bound Arsenic Trioxide (As2O3).

Authors:  Yunlong Li; Guopeng Yu; Qiaoxing Li; Weilu Wang; Xiangqian Shen; Hua Liu; Ruijiang Liu
Journal:  PLoS One       Date:  2015-04-27       Impact factor: 3.240

8.  CUSP9* treatment protocol for recurrent glioblastoma: aprepitant, artesunate, auranofin, captopril, celecoxib, disulfiram, itraconazole, ritonavir, sertraline augmenting continuous low dose temozolomide.

Authors:  Richard E Kast; Georg Karpel-Massler; Marc-Eric Halatsch
Journal:  Oncotarget       Date:  2014-09-30

9.  Artesunate induces apoptosis and inhibits the proliferation, stemness, and tumorigenesis of leukemia.

Authors:  Shengmei Chen; Silin Gan; Lijie Han; Xue Li; Xiaoqing Xie; Dianbin Zou; Hui Sun
Journal:  Ann Transl Med       Date:  2020-06
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.